Finance

Moderna (MRNA) Was Removed From the Nasdaq-100 and Is Going Back In. What Changed?

Retension Pharmaceuticals prices IPO at $12 per share on Nasdaq

Nasdaq Drops Over 300 Points After OpenAI's Revenue Comes In $20 Billion Short

Tokenization could unleash tens of billions of dollars in trapped capital, Nasdaq CEO says